Business Wire

“Genome Editing: The Next Frontier”: 4th Conference in the Bridging Biomedical Worlds Series

Del

The Fondation IPSEN today announced the fourth Bridging Biomedical Worlds Conference, “Genome Editing: The Next Frontier”, which will be focused on the improvement and most recent applications of genome editing tools. This meeting will take place in Singapore from February 5 th to 7 th 2018.

The Significance of Genome Editing

For decades, scientists have searched for a genome editing tool that will facilitate the easy and sustainable modification of genes in health and biomedical research. The engineering of CRISPR-Cas9 five years ago proved to be a breakthrough in the field. CRISPR-Cas9 is a natural defense system in bacteria that has been modified to allow any DNA modification in all living species. CRISPR-Cas9 technology has opened up promising avenues in various scientific fields, and is being utilized in the development of innovative therapies for cancer and other infectious and genetic diseases.

The 2018 Bridging Biomedical Worlds Conference, “Genome Editing: The Next Frontier”, will be held in Singapore from February 5th to 7th 2018. Feature a line-up of internationally renowned speakers who are experts in their fields, the Conference will cover a range of topics including natural bacterial immune mechanisms, the next generation of genome editing tools, and applications of genome editing tools in scientific discovery and in therapy.

This event is jointly organized by Fondation IPSEN, AAAS/Science, AAAS/Science Translational Medicine, and A*STAR’s Institute of Molecular and Cell Biology (IMCB).

Program

     

Keynote Lecture

Engineering Smarter T-cells

Carl JUNE
 

Session I

CRISPRs for Attack and Defense

Avec Dipali SASHITAL, Rotem SOREK, Seokjoong KIM
 

Session II

Advances in Genome Editing

Avec Nicole GAUDELLI, Martin JINEK, Farren ISAACS, Gene YEO, Fabrice VANDEPUT
 

Session III

CRISPRs as a Discovery Tool

Avec Mashito IKAWA, Neville SANJANA, David BIKARD
 

Session IV

Table ronde : Scientific Challenges for Genome Editing

 

Session V

Therapeutic Applications of Gene Editing

Avec Suk See DE RAVIN, Paula CANNON, Eric OLSON, Waseem QASIM, Andrea CRISANTI
 

Session VI

Table ronde : Therapeutic Challenges for Genome Editing

 

Keynote Lecture

Functional Genomics to Study Cancer

David SABATINI

This scientific meeting has been recognized “INNOVATION YEAR 2018” by the French Singapore Embassy. This label has been launched in 2017 by Mister François Hollande, former President of the French Republic, and Lee Hsien Loong, Singapore prime minister, to reinforce bilateral initiatives and collaboration in key sectors like health or biotechnology.

Detailed program: https://www.bridgingbiomedicalworlds.com

To RSVP for the Conference, please contact: yannick.tanguy@ipsen.com

About the Bridging Biomedical Worlds series

The Fondation IPSEN and the American Association for the Advancement of Science launched a new Conference series in 2014 entitled “Bridging Biomedical Worlds” to facilitate the global exchange of knowledge about important advances in key research areas, and boost communication and cooperation among researchers, clinicians, and industry scientists from East and West. Each year a ground-breaking topic is tackled with a local partner in a different country in Asia.

More info on the previous meetings: https://www.bridgingbiomedicalworlds.com/previous-edition/

About A*STAR’s Institute of Molecular and Cell Biology (IMCB)

The Institute of Molecular and Cell Biology (IMCB) was launched on 23 January 1985, with its official opening ceremony held on 2 October 1987 at the National University of Singapore (NUS). It subsequently became an autonomous research institute (RI) of A*STAR, moving to Biopolis in 2004. IMCB’s vision is to be a premier cell and molecular biology institute which addresses the mechanistic basis of human diseases and its mission is to conduct cutting-edge discovery research in disease pathways; to groom early career researchers to be future leaders in research; and to collaborate with medical and industry communities for research impact. IMCB plays an important role training and recruiting scientific talents, and has contributed to the development of other research entities in Singapore. Its success in fostering a biomedical research culture in Singapore has catalysed Singapore’s transformation into an international hub for biomedical research, development and innovation.

Funded primarily by the Biomedical Research Council (BMRC) of A*STAR, IMCB’s Discovery research comprises 5 major programmes: Cancer Cell Signalling, Multi-Modal Molecular (M3) Biology, Epigenetics and Diseases, iPS cell and Regenerative Medicine, and Technology and Translation. IMCB’s technologies and platforms focus on Genome-wide RNAi, Humanized Mouse Models, Proteomics and Protein Engineering, Gene Therapy and Gene Editing, and Molecular Histopathology.

IMCB strives to maintain the scientific excellence of PI-driven research and at the same time aims to promote collaborative team-based projects of medical and industrial relevance.

For more information about IMCB, visit www.imcb.a-star.edu.sg.

About AAAS/Science

The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science (www.sciencemag.org) as well as Science Translational Medicine (www.sciencetranslationalmedicine.org), Science Signaling (www.sciencesignaling.org), and Science Advances (http://advances.sciencemag.org/). AAAS was founded in 1848, and includes some 261 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 1 million. The non-profit AAAS (www.aaas.org) is open to all and fulfills its mission to “advance science and serve society” not only by publishing the very best scientific research but also through initiatives in science policy, international programs and science education.
www.sciencemag.org

About AAAS/Science Translational Medicine

Science Translational Medicine was launched in October 2009. The goal of Science Translational Medicine is to promote human health by providing a forum for communicating the latest biomedical research findings from basic, translational, and clinical researchers from all established and emerging disciplines relevant to medicine. Despite 50 years of advances in our fundamental understanding of human biology and the emergence of powerful new technologies, the translation of this knowledge into effective new treatments and health measures has been slow. This paradox illustrates the daunting complexity of the challenges faced by translational researchers as they apply the basic discoveries and experimental approaches of modern science to the alleviation of human suffering. A major goal of Science Translational Medicine is to publish papers that identify and fill the scientific knowledge gaps at the junction of basic research and medical application in order to accelerate the translation of scientific knowledge into new methods for preventing, diagnosing and treating human disease.
www.sciencetranslationalmedicine.org

The Fondation IPSEN

Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. The long-standing mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche. Moreover, the Fondation IPSEN has created several series of meetings in partnership with the Salk Institute, the Karolinska Institute as well as with the scientific journals Cell and Science. The Fondation IPSEN produced several hundred publications and more than 250 scientists have been awarded prizes and grants.
www.fondation-ipsen.org

Contact information

For further information, and to RSVP for the Conference:
Fondation IPSEN
Yannick TANGUY, Tel: +33 (0)6 81187860
E-mail: yannick.tanguy@ipsen.com
www.fondation-ipsen.org
Twitter: @FondationIpsen (#BridgBioWorlds)
LinkedIn: Fondation IPSEN
YouTube: Fondation IPSEN video

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third

Tradeshift Announces Q3 2018 Results19.10.2018 11:00Pressemelding

Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between

Alibaba’s Robust Ecosystem Supercharges 2018 11.11 Global Shopping Festival19.10.2018 10:15Pressemelding

Alibaba Group Holding Limited (NYSE:BABA) today officially kicked off the 2018 11.11 Global Shopping Festival in China’s capital, promising this year’s mega-event will be the largest-ever in terms of scale and reach. Businesses within the Alibaba ecosystem will jointly offer hundreds of millions of consumers an enriching experience that supports their pursuit of high-quality products, entertainment and fast, reliable services. The Festival will also demonstrate the enthusiasm of consumers and brands embracing Alibaba’s New Retail strategy – the convergence of online and offline retail through technology. “This year marks the 10th anniversary of 11.11. On the back of China’s explosive digital transformation, the Festival’s astounding growth over the past decade has powered the steady growth of quality consumption sought by Chinese shoppers. The evolution also showcases the development of the Alibaba ecosystem over time expanding well beyond e-commerce,” said Alibaba Group CEO Daniel Zha